Some studies have shown a poor safety profile for dacomitinib (Li et al., 2024), but there is no evidence of a significant difference between dacomitinib and other EGFR-TKIs in terms of restrictive lung disease. Here, EGFR is linked to Restrictive ventilatory defect.